📣 VC round data is live. Check it out!

ST Pharm Valuation Multiples

Discover ST Pharm's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Jiuzhou Pharmaceutical, Jubilant Pharmova, PolyPeptide, Anupam Rasayan India and more.

ST Pharm Overview

About ST Pharm

St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm’s business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical’s business and development of oligonucleotide therapeutics. The company’s products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.


Founded

2008

HQ

South Korea

Employees

N/A

Financials (LTM)

Revenue: $246M
EBITDA: $66M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

ST Pharm Financials

ST Pharm reported last 12-month revenue of $246M and EBITDA of $66M.

In the same LTM period, ST Pharm generated $101M in gross profit, $66M in EBITDA, and $41M in net income.

Revenue (LTM)


ST Pharm P&L

In the most recent fiscal year, ST Pharm reported revenue of $227M and EBITDA of $61M.

ST Pharm is profitable as of last fiscal year, with gross margin of 40%, EBITDA margin of 27%, and net margin of 17%.

See analyst estimates for ST Pharm
LTMLast FY202320242025202620272028
Revenue$246M$227M$189M$181M$219M
Gross Profit$101M$90M$74M$64M$90M
Gross Margin41%40%39%35%41%
EBITDA$66M$61M$35M$50M$61M
EBITDA Margin27%27%18%28%28%
EBIT Margin18%17%12%10%17%
Net Profit$41M$38M$13M$23M$36M
Net Margin17%17%7%13%17%
Net Debt-$30M---

Financial data powered by Morningstar, Inc.

ST Pharm Stock Performance

ST Pharm has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


ST Pharm's stock price is $81.65.

ST Pharm share price decreased by 8.3% in the last 30 days, and increased by 57.5% in the last year.

ST Pharm has an EPS (earnings per share) of $1.82.

See more trading valuation data for ST Pharm
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-5.0%-8.3%-16.8%57.5%$1.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

ST Pharm Valuation Multiples

ST Pharm trades at 6.5x EV/Revenue multiple, and 24.5x EV/EBITDA.

See NTM and 2027E valuation multiples for ST Pharm

EV / Revenue (LTM)


ST Pharm Financial Valuation Multiples

As of June 4, 2026, ST Pharm has market cap of $2B and EV of $2B.

ST Pharm has a P/E ratio of 40.8x.

LTMLast FY202320242025202620272028
EV/Revenue6.5x7.1x8.5x8.9x7.3x
EV/EBITDA24.5x26.2x46.3x31.9x26.2x
EV/EBIT37.0x42.7x72.5x87.7x44.2x
EV/Gross Profit15.9x17.8x21.7x25.3x17.8x
P/E40.8x44.9x130.4x73.6x46.4x
EV/FCF79.6xn/m(57.6x)92.6x(73.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified ST Pharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

ST Pharm Margins & Growth Rates

ST Pharm grew revenue by 20% and EBITDA by 24% in the last fiscal year.

In the most recent fiscal year, ST Pharm reported gross margin of 40%, EBITDA margin of 27%, and net margin of 17%.

See estimated margins and future growth rates for ST Pharm

ST Pharm Margins

Last FY202420252026202720282029
Gross Margin40%35%41%41%
EBITDA Margin27%28%28%28%
EBIT Margin17%10%17%19%
Net Margin17%13%17%17%
FCF Margin(1%)10%(10%)19%

ST Pharm Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth20%(4%)21%24%
Gross Profit Growth24%(14%)42%24%
EBITDA Growth24%45%22%24%
EBIT Growth37%(17%)98%41%
Net Profit Growth24%77%58%28%
FCF Growth(2263%)(162%)(227%)(332%)

Data powered by FactSet, Inc. and Morningstar, Inc.

ST Pharm Operational KPIs

ST Pharm's Rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ST Pharm's Rule of X is 88% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for ST Pharm
LTMLast FY202320242025202620272028
Rule of 4047%52%---
Bessemer Rule of X78%88%---
S&M Expenses to Revenue-2%2%2%2%
G&A Expenses to Revenue-2%2%2%2%
R&D Expenses to Revenue-7%11%8%7%
Opex to Revenue-24%28%25%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

ST Pharm Competitors

ST Pharm competitors include Jiuzhou Pharmaceutical, Jubilant Pharmova, PolyPeptide, Anupam Rasayan India, Syngene, AbCellera, Fortrea, Bora Pharmaceuticals, Fagron and PharmaResearch.

Most ST Pharm public comparables operate across Contract Research & Manufacturing, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Jiuzhou Pharmaceutical1.8x1.8x6.8x6.7x
Jubilant Pharmova2.1x2.1x13.9x13.4x
PolyPeptide3.7x3.4x32.4x24.0x
Anupam Rasayan India11.3x8.9x39.5x36.0x
Syngene4.5x4.4x17.5x17.3x
AbCellera20.0x26.5x(8.6x)(7.2x)
Fortrea0.9x0.9x12.8x12.2x
Bora Pharmaceuticals3.0x2.9x8.4x10.1x

This data is available for Pro users. Sign up to see all ST Pharm competitors and their valuation data.

Start Free Trial

Investments by ST Pharm

ST Pharm has invested in 1 company to date.

Latest investment by ST Pharm was on March 22nd 2021. ST Pharm invested in Pinot Bio in their $5M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by ST Pharm

Pinot Bio
Description
Pinot Bio is a Seoul-headquartered biotechnology company engineering novel anticancer therapeutics targeting tumor microenvironments and immune checkpoints. Its pipeline features bispecific antibodies and PROTACs advancing through preclinical stages for solid tumors including lung and breast cancers. The firm collaborates with Korean research institutes on IND filings and early clinical trials.
HQ CountrySouth Korea
HQ City
Suwon
Deal Date22 Mar 2021
RoundSeries A
Raised$5M
InvestorsST Pharm
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all ST Pharm investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About ST Pharm

When was ST Pharm founded?ST Pharm was founded in 2008.
Where is ST Pharm headquartered?ST Pharm is headquartered in South Korea.
Is ST Pharm publicly listed?Yes, ST Pharm is a public company listed on Korea Exchange.
What is the stock symbol of ST Pharm?ST Pharm trades under 237690 ticker.
When did ST Pharm go public?ST Pharm went public in 2016.
Who are competitors of ST Pharm?ST Pharm main competitors include Jiuzhou Pharmaceutical, Jubilant Pharmova, PolyPeptide, Anupam Rasayan India, Syngene, AbCellera, Fortrea, Bora Pharmaceuticals, Fagron, PharmaResearch.
What is the current market cap of ST Pharm?ST Pharm's current market cap is $2B.
What is the current revenue of ST Pharm?ST Pharm's last 12 months revenue is $246M.
What is the current revenue growth of ST Pharm?ST Pharm revenue growth (NTM/LTM) is 20%.
What is the current EV/Revenue multiple of ST Pharm?Current revenue multiple of ST Pharm is 6.5x.
What is the current EBITDA of ST Pharm?ST Pharm's last 12 months EBITDA is $66M.
What is ST Pharm's EBITDA margin?ST Pharm's last 12 months EBITDA margin is 27%.
What is the current EV/EBITDA multiple of ST Pharm?Current EBITDA multiple of ST Pharm is 24.5x.
What is the current FCF of ST Pharm?ST Pharm's last 12 months FCF is $20M.
What is ST Pharm's FCF margin?ST Pharm's last 12 months FCF margin is 8%.
What is the current EV/FCF multiple of ST Pharm?Current FCF multiple of ST Pharm is 79.6x.
How many companies ST Pharm has acquired to date?ST Pharm hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies ST Pharm has invested to date?As of June 2026, ST Pharm has invested in 1 company.
What was the last ST Pharm investment?On 22nd March 2021 ST Pharm invested in Pinot Bio, participating in a $5M Series A round.
In what companies ST Pharm invested in?ST Pharm invested in Pinot Bio.

See public comps similar to ST Pharm

Lists including ST Pharm

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial